The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The ACR Continues Fight to Block Medicare Part B Demo Project: Rule Expected in Fall 2016

The ACR Continues Fight to Block Medicare Part B Demo Project: Rule Expected in Fall 2016

August 4, 2016 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ACR will seek Congressional action if the Medicare Part B demonstration project proposed by the Centers for Medicare & Medicaid Services (CMS) is not significantly altered by the agency. Today, Medicare Part B generally pays physicians and hospital outpatient departments the average sales price of a drug, plus a 6% add-on, minus reductions required by the sequester. The proposed model would test whether changing the add-on payment to 2.5% (minus the sequester) plus a flat fee payment of $16.80 per drug per day changes prescribing incentives and leads to improved quality and value. CMS would update the flat fee at the beginning of each year by the percentage increase in the consumer price index for medical care for the most recent 12-month period. The comment period for the proposal ended in May, and if implemented as proposed, the project will begin in late 2016, run for five years and affect all rheumatology practices.

You Might Also Like
  • The Fight Against the Medicare Part B Demonstration Project
  • The ACR Opposes Part B Payment Demo & Other Highlights from the AMA HOD Meeting
  • ACR Leads Fight Against Proposed Reimbursement Cuts to E/M Services
Also By This Author
  • Alliance Working to Rein in Power of PBMs

ACR President Joan Von Feldt, MD, MSEd, describes the demonstration project as “too broad in scope and fundamentally flawed. If [it] is not changed in scope, then our resolution is to go to Congress to legislate a change.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This resolve is shared by several other medical societies, including the American Academy of Ophthalmology and the American Society of Clinical Oncology, which have joined the ACR in calling on the American Medical Association to “support and actively work to advance Congressional action to block the demonstration project through legislation or restriction of funding,” a resolution that the AMA’s House of Delegates passed in its most recent meeting.

What the ACR Is Doing & Why
Through the College’s Legislative Action Center, ACR members have forwarded more than 4,000 letters to Congress decrying the project, and they have penned more than 40 opinion articles in publications across the country. “Of all the issues I have been involved in with the ACR, this issue has been the most successful in terms of [the] membership standing up and making a difference,” says Will Harvey, MD, chair of the ACR’s Government Affairs Committee.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One of the ACR’s concerns is how the demonstration project would affect payment for infusion therapies that are administered in a rheumatologist’s office and other expensive rheumatology therapies. Because of the size of the reimbursement cut, and the effect of sequester, providing biologics may not be cost effective for rheumatologists – particularly those purchasing medications for prices above the average sales price. Additionally, there are no less-expensive equally-effective alternatives for biologics, in which the small flat fee might offset the reimbursement cuts. Patients will incur increased cost, burden and risk if they seek therapy elsewhere.

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: Centers for Medicare and Medicaid Services (CMS), Legislative Action Center, Medicare Part B

You Might Also Like:
  • The Fight Against the Medicare Part B Demonstration Project
  • The ACR Opposes Part B Payment Demo & Other Highlights from the AMA HOD Meeting
  • ACR Leads Fight Against Proposed Reimbursement Cuts to E/M Services
  • CMS Cancels Medicare Part B Demonstration Project

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)